Per 21 CFR 1271.155, an HCT/P establishment may request an exemption or alternative procedure to any Donor Eligibility and/or Current Good Tissue Practices regulation. The request for exemption or alternative procedure must be submitted to the appropriate center director at the FDA; however, CBER has redelegated the authority to issue a response to the director and deputy director of the Office of Cellular, Tissue and Gene Therapies. The request must include supporting documentation, including all relevant valid scientific data, and must contain either information justifying the requested exemption from the requirement or a description of a proposed alternative method of meeting the requirement. Additional information on requesting an exemption or alternative procedure is available.
Cell Notes: Looking Back, Moving Forward: Exciting New Developments in Biotherapies
December 18, 2024
FDA Workshop to Focus on Generating Scientific Evidence to Facilitate CT Development
December 18, 2024
Advanced Therapies Week: AABB to Host Fireside Chat on Sustainable Donor Sourcing
December 13, 2024